IBDEI1DO ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,24416,2)
 ;;=^123902
 ;;^UTILITY(U,$J,358.3,24417,0)
 ;;=441.9^^136^1494^2
 ;;^UTILITY(U,$J,358.3,24417,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24417,1,1,0)
 ;;=1^441.9
 ;;^UTILITY(U,$J,358.3,24417,1,2,0)
 ;;=2^ANEURYSM,AORTIC W/O RUPTURE,SITE UNSPEC
 ;;^UTILITY(U,$J,358.3,24417,2)
 ;;=^9277
 ;;^UTILITY(U,$J,358.3,24418,0)
 ;;=442.9^^136^1494^3
 ;;^UTILITY(U,$J,358.3,24418,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24418,1,1,0)
 ;;=1^442.9
 ;;^UTILITY(U,$J,358.3,24418,1,2,0)
 ;;=2^ANEURYSM,NON-AORTIC,SITE UNSPEC
 ;;^UTILITY(U,$J,358.3,24418,2)
 ;;=^7390
 ;;^UTILITY(U,$J,358.3,24419,0)
 ;;=710.3^^136^1494^6
 ;;^UTILITY(U,$J,358.3,24419,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24419,1,1,0)
 ;;=1^710.3
 ;;^UTILITY(U,$J,358.3,24419,1,2,0)
 ;;=2^DERMATOMYOSITIS
 ;;^UTILITY(U,$J,358.3,24419,2)
 ;;=^33162
 ;;^UTILITY(U,$J,358.3,24420,0)
 ;;=446.5^^136^1494^7
 ;;^UTILITY(U,$J,358.3,24420,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24420,1,1,0)
 ;;=1^446.5
 ;;^UTILITY(U,$J,358.3,24420,1,2,0)
 ;;=2^GIANT CELL ARTERITIS
 ;;^UTILITY(U,$J,358.3,24420,2)
 ;;=^117658
 ;;^UTILITY(U,$J,358.3,24421,0)
 ;;=446.20^^136^1494^8
 ;;^UTILITY(U,$J,358.3,24421,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24421,1,1,0)
 ;;=1^446.20
 ;;^UTILITY(U,$J,358.3,24421,1,2,0)
 ;;=2^HYPERSENSITIVITY ANGIITIS, UNS
 ;;^UTILITY(U,$J,358.3,24421,2)
 ;;=^60279
 ;;^UTILITY(U,$J,358.3,24422,0)
 ;;=446.3^^136^1494^9
 ;;^UTILITY(U,$J,358.3,24422,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24422,1,1,0)
 ;;=1^446.3
 ;;^UTILITY(U,$J,358.3,24422,1,2,0)
 ;;=2^LETHAL MIDLINE GRANULOMA
 ;;^UTILITY(U,$J,358.3,24422,2)
 ;;=^52905
 ;;^UTILITY(U,$J,358.3,24423,0)
 ;;=446.1^^136^1494^10
 ;;^UTILITY(U,$J,358.3,24423,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24423,1,1,0)
 ;;=1^446.1
 ;;^UTILITY(U,$J,358.3,24423,1,2,0)
 ;;=2^MUCOCUTANEOUS LYMPH SYND (MCLS)
 ;;^UTILITY(U,$J,358.3,24423,2)
 ;;=^79494
 ;;^UTILITY(U,$J,358.3,24424,0)
 ;;=443.9^^136^1494^11
 ;;^UTILITY(U,$J,358.3,24424,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24424,1,1,0)
 ;;=1^443.9
 ;;^UTILITY(U,$J,358.3,24424,1,2,0)
 ;;=2^PERIPH VASCULAR DIS NOS
 ;;^UTILITY(U,$J,358.3,24424,2)
 ;;=^184182
 ;;^UTILITY(U,$J,358.3,24425,0)
 ;;=446.0^^136^1494^12
 ;;^UTILITY(U,$J,358.3,24425,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24425,1,1,0)
 ;;=1^446.0
 ;;^UTILITY(U,$J,358.3,24425,1,2,0)
 ;;=2^POLYARTERITIS NODOSA
 ;;^UTILITY(U,$J,358.3,24425,2)
 ;;=^91874
 ;;^UTILITY(U,$J,358.3,24426,0)
 ;;=710.4^^136^1494^13
 ;;^UTILITY(U,$J,358.3,24426,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24426,1,1,0)
 ;;=1^710.4
 ;;^UTILITY(U,$J,358.3,24426,1,2,0)
 ;;=2^POLYMYOSITIS
 ;;^UTILITY(U,$J,358.3,24426,2)
 ;;=^186822
 ;;^UTILITY(U,$J,358.3,24427,0)
 ;;=452.^^136^1494^14
 ;;^UTILITY(U,$J,358.3,24427,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24427,1,1,0)
 ;;=1^452.
 ;;^UTILITY(U,$J,358.3,24427,1,2,0)
 ;;=2^PORTAL VEIN THROMBOSIS
 ;;^UTILITY(U,$J,358.3,24427,2)
 ;;=^269815
 ;;^UTILITY(U,$J,358.3,24428,0)
 ;;=714.2^^136^1494^15
 ;;^UTILITY(U,$J,358.3,24428,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24428,1,1,0)
 ;;=1^714.2
 ;;^UTILITY(U,$J,358.3,24428,1,2,0)
 ;;=2^RHEUMATOID ARTHRITIS,SYSTEMIC
 ;;^UTILITY(U,$J,358.3,24428,2)
 ;;=^272111
 ;;^UTILITY(U,$J,358.3,24429,0)
 ;;=135.^^136^1494^16
 ;;^UTILITY(U,$J,358.3,24429,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24429,1,1,0)
 ;;=1^135.
 ;;^UTILITY(U,$J,358.3,24429,1,2,0)
 ;;=2^SARCOIDOSIS
 ;;^UTILITY(U,$J,358.3,24429,2)
 ;;=^107916
 ;;^UTILITY(U,$J,358.3,24430,0)
 ;;=710.0^^136^1494^17
 ;;^UTILITY(U,$J,358.3,24430,1,0)
 ;;=^358.31IA^2^2
 ;;
 ;;$END ROU IBDEI1DO
